Tempol is under clinical development by DMK Pharmaceuticals and currently in Phase II for Radiodermatitis. According to GlobalData, Phase II drugs for Radiodermatitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Tempol LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tempol overview

Tempol is under development for the radiation-induced skin toxicity, prevention of radiation-induced oral mucositis, chemotherapy-induced toxicities, treatment of  ataxia-telangiectasia (Louis-Bar syndrome), radiation induced dermatitis, recurrent glioblastoma multiforme, prostate cancer, doxorubicin induced toxicities, macular degeneration, cisplatin toxicities and paclitaxel induced toxicities. The drug candidate is administered orally and topically as a capsule and as a gel. MTS-01 (Tempol) is a piperidine nitroxide. Tempol is a membrane-permeable radical scavenger. It acts by targeting HIF-1 and HIF-2. It was under development for the treatment of alopecia and depression. 

It was under development for the treatment of ARDS, cytokine storm due to COVID-19 disease, ataxia telangiectasia and peripheral neuropathy.

DMK Pharmaceuticals overview

DMK Pharmaceuticals (DMK), formerly Adamis Pharmaceuticals Corporation, is a commercial-stage neuro-biotech company that develops and commercializes products for the treatment of opioid overdose and substance use disorders. The company’s pipeline includes SYMJEPI, ZIMHI, DPI-125, DPI-221 and DPI-289. Its pipeline candidates treat anaphylaxis, opioid overdose, opioid use disorder, benign prostatic hyperplasia and parkinson’s disease. DMK develops products in the form of injections, gels and capsules for the treatment of allergies, opioid overdose and respiratory and inflammatory disease. The company supplies its products to doctors, ambulatory surgery centers, healthcare systems, hospitals and veterinarians across the US. DMK is headquartered in San Diego, California, the US.

For a complete picture of Tempol’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.